Table I.

Average anti-proliferative and cytotoxic potencies of MTAs in breast cancer cell lines with different doubling times

	ER/HER2 status	Doubling Time (h)	Average GI50 (nM)	Average TGI (nM)	Average LC50 (nM)
MDA-MB-468	−/−	62.8	1.4	2.8	11
SK-BR-3	−/+	44.6	1.8	3.5	62
Hs 578T	−/−	43.7	2.5	4.9*	18*
MCF7	+/−	44.2	2.3	5.8	410***
T-47D	+/−	47.4	5.8	92**	> 5,000
MDA-MB-231	−/−	31.1	4.9	132***	> 5,000
HCC1937	−/−	49.9	6.5	> 5,000	> 5,000
BT-549	−/−	20.9	8.4	> 5,000	> 5,000

^*One of the drugs did not reach this criterion;

^**two of the drugs did not reach this criterion;

^***three of the drugs did not reach this criterion